

**23.** The method of claim **13**, wherein said antibody or antibody fragment is administered prior to infection or after infection.

**24.** The method of claim **13**, wherein said subject is a pregnant female, a sexually active female, or a female undergoing fertility treatments.

**25.** The method of claim **13**, wherein delivering comprises antibody or antibody fragment administration, or genetic delivery with an RNA or DNA sequence or vector encoding the antibody or antibody fragment.

**26-35.** (canceled)

**36.** A hybridoma or engineered cell encoding an antibody or antibody fragment wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.

**37-46.** (canceled)

**47.** A vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.

**48-56.** (canceled)

**57.** A vaccine formulation comprising one or more expression vectors encoding a first antibody or antibody fragment characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.

**58-75.** (canceled)

**76.** A method of determining the antigenic integrity, correct conformation and/or correct sequence of an influenza A virus hemagglutinin antigen comprising:

- (a) contacting a sample comprising said antigen with a first antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and
- (b) determining antigenic integrity, correct conformation and/or correct sequence of said antigen by detectable binding of said first antibody or antibody fragment to said antigen.

**77-96.** (canceled)

**97.** A human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, wherein said antibody binds to a transiently accessible epitope located at an interface of the influenza A hemagglutinin trimer, and/or provides in vivo protection against influenza A viruses, or that that preferentially binds to uncleaved HA on the surface of virus-infected cells.

**98-105.** (canceled)

**106.** The method of claim **13**, wherein said antibody or antibody fragment has an antiviral molecule attached thereto.

\* \* \* \* \*